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Abstract One of the ultimate goals in transplantation is to
develop novel therapeutic methods for induction of donor-
speciﬁc tolerance to reduce the side effects caused by the
generalized immunosuppression associated to the currently
used pharmacologic regimens. Interaction or phagocytosis
of cells in early apoptosis exerts potent anti-inﬂammatory
and immunosuppressive effects on antigen (Ag)-presenting
cells (APC) like dendritic cells (DC) and macrophages. This
observationledtotheideathatapoptoticcell-basedtherapies
could be employed to deliver donor-Ag in combination
with regulatory signals to recipient’s APC as therapeutic
approach to restrain the anti-donor response. This review
describes the multiple mechanisms by which apoptotic cells
down-modulate the immuno-stimulatory and pro-inﬂam-
matoryfunctionsofDCandmacrophages,andtheroleofthe
interaction between apoptotic cells and APC in self-toler-
ance and in apoptotic cell-based therapies to prevent/treat
allograft rejection and graft-versus-host disease in murine
experimentalsystemsandinhumans.Italsoexplorestherole
that in vivo-generated apoptotic cells could have in the
beneﬁcial effects of extracorporeal photopheresis, donor-
speciﬁc transfusion, and tolerogenic DC-based therapies in
transplantation.
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Introduction
Transplantation of organs, tissues or cells has become a
common surgical procedure that frequently serves as the
only life-saving treatment available for end-stage organ
disorders. Allogeneic (allo) grafts are deﬁned as organs/tis-
sues/cells transplanted between totally or partially Major
Histocompatibility (MHC) antigen (Ag)-mismatched indi-
vidualsofthesamespecies.Accordingtothetimingofonset,
there are three main types of allograft rejection: hyperacute,
acute and chronic. Hyperacute rejection takes place within
minutes or hours after transplantation and is caused by
deposition of pre-formed circulating antibodies (Ab) on the
endothelium of the graft vasculature and the consequent
complement cascade activation. This type of rejection is in
general preventable and rarely occurs. Acute rejection
occurswithinweeksormonthsaftertransplantation surgery,
iscausedbyinnateandadaptiveimmuneresponses,thelatter
mediated by donor-reactive T cells and anti-donor allo-
antibodies (alloAb), and is treatable by pharmacologic
immuno-suppression. Chronic rejection takes place months
oringeneralyearsaftertransplantation,iscausedbyimmune
and non-immune mechanisms, and does not respond to the
currently employed immunosuppressive agents.
The development of nonspeciﬁc immunosuppressive
agents and the better management of their therapeutic
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DOI 10.1007/s10495-010-0469-9application and synergistic effects have decreased signiﬁ-
cantly the incidence of acute allograft rejection in the
clinics. However, the currently used immunosuppressive
drugs have shown little or no impact on chronic rejection
and therefore on overall long-tern allograft survival.
Importantly, long-term pharmacological immunosuppres-
sion is associated with toxicity and increased incidence of
malignancies and infectious and metabolic diseases.
Therefore, there is a need for the development of new
donor-speciﬁc immunosuppressive therapies to control the
mechanisms of allo-recognition that lead to graft rejection,
and to reduce harmful side-effects of generalized immu-
nosuppression. The ﬁnding that apoptotic cells exert potent
anti-inﬂammatory and immunoregulatory effects on Ag-
presenting cells (APC) of the immune system has paved the
way for the development of novel apoptotic cell-based
therapies that have been used successfully in delaying
transplant rejection and treating T cell-mediated autoim-
mune disorders in murine experimental models.
Role of APC in initiation of allograft rejection
One of the critical mechanisms of acute rejection is the T
cell response mounted against donor MHC Ag. T cells
recognize antigenic peptides presented by MHC molecules
with the help of professional APC such as dendritic cells
(DC), or amateur APC like monocyte, macrophages and B
cells. Among professional APC, mature/activated DC are
the most efﬁcient at priming naı ¨ve T cells which exhibit a
higher threshold of activation than memory T cells.
Transplanted organs are populated by immature DC that
are phagocytic with high capability for Ag internalization
and processing, but that exhibit weak stimulatory capacity
for naı ¨ve T cells due to the low levels of Ag-presenting and
costimulatory molecules on the DC surface. Pro-inﬂam-
matory mediators released following transplant surgery and
due to the effects of ischemia–reperfusion injury on the
graft are sufﬁcient to trigger the mechanisms of maturation/
activation of graft-resident and graft-inﬁltrating DC. These
maturing DC migrate as passenger leukocytes out of the
graft into secondary lymphoid tissues of the recipient,
where they activate donor-speciﬁc naı ¨ve and memory T
cells. However, besides their role in elicitation allo-
immunity and as initiators of graft rejection, DC are critical
to induce and maintain T cell peripheral tolerance, in
particular following interaction with apoptotic cells.
Immunoregulatory effects of apoptotic cells on APC
It was originally assumed that the rapid clearance of
apoptotic cells in vivo, before cell lysis and leakage of
intracellular toxic mediators take place, was the reason by
which phagocytosis of apoptotic cells by macrophages or
immature DC does not elicit inﬂammatory or immune
responses in steady-state conditions. Voll et al. [1] were the
ﬁrst to realize that apoptotic cells exert an active and potent
immunosuppressive effect on monocytes, promoting
secretion of interleukin (IL)-10 and decreasing release of
the pro-inﬂammatory cytokines Tumor Necrosis Factor
(TNF)-a, IL-1b and IL-12. They also demonstrated that the
immunoregulatory effect of apoptotic cells on APC is
conserved between mammalian species and is independent
of the apoptosis-inducing stimulus [1]. This profound
down-regulatory effect of apoptotic cells on immunity
occurs in professional and non-professional phagocytes and
in non-phagocytic cells [2]. Accumulated evidence has
shown that interaction and/or internalization of apoptotic
cells by immature DC does not induce expression of the
DC maturation-markers MHC class-II, CD40, CD80, CD86
and CD83 in vitro or in vivo, even after challenge with
lipopolysaccharide (LPS), CD40-signaling, TNF-a or
monocyte-conditioned medium [3–8]. By contrast, phago-
cytosis of cells undergoing primary necrosis or dying cells
derived from virally-infected, activated or stressed cells
promote DC maturation [3, 4, 9–11]. Besides the intrinsic
characteristics of the dying cells, the pattern of opsonins
deposited on the surface of apoptotic cells, the microen-
vironment where apoptotic cells die, and the efﬁciency of
apoptotic cell clearance by phagocytes are critical factors
that determine the outcome of the innate and adaptive
immune responses [12].
It was initially assumed that, unlike early apoptotic cells
which retain membrane integrity and exert immunosup-
pressive effects, late apoptotic cells (also known as sec-
ondarily necrotic cells) similarly to cells undergoing
primary necrosis promote inﬂammation and immunity,
since in both cases cells lose their membrane integrity and
release potential pro-inﬂammatory mediators. However,
Patel et al. [13] have shown in vitro that the mitogen-
activated protein kinase (MAPK) signaling events triggered
in macrophages by early apoptotic cells (inhibition of
ERK1/2 and activation c-Jun N-terminal kinase and p38)
are similar to those induced by late apoptotic cells and that,
in both cases, were dominant over those triggered by
necrotic cells. The inhibitory activity of late apoptotic cells
on macrophages required the presence of the plasma
membrane of the dying cells, and did not depend on soluble
mediators released by the late apoptotic cells [13]. These
results contradict the established paradigm that states that
delayed clearance of apoptotic cells in vivo leads to
accumulation of cells in late apoptosis that, by releasing
pro-inﬂammatory mediators, promote auto-immunity. By
contrast, they suggest that in those experimental models of
autoimmunity associated to impaired clearance of
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opsonins necessary for recognition of apoptotic cells,
autoimmunity could be triggered, to some extent by the
inability of the apoptotic cells to deliver inhibitory signals
to APC, and not by the continuous release of pro-inﬂam-
matory mediators by non-internalized late apoptotic cells
accumulated in the extracellular space [13].
DC that internalize cells in early apoptosis exhibit a
selective decrease in the levels of mRNA and secretion
of the pro-inﬂammatory cytokines IL-1a, IL-1b, IL-6,
IL-12p70 and TNF-a, while secreting normal or increased
amounts of immunosuppressive Transforming Growth
Factor (TGF)-b1 and IL-10, even in the presence of LPS
[4, 14–16]. Phagocytosis of apoptotic neutrophils decreases
DC secretion of IL-23, a cytokine involved in differentia-
tion of Th17 lymphocytes and maintenance of Th1 memory
[17]. The immunoregulatory effects are restricted to those
DC that phagocytose apoptotic cells and not to bystander
cells, indicating that the mechanism of DC inhibition
involves cell-to-cell contact since it (1) requires recogni-
tion of ligands on the apoptotic cell surface through
receptors expressed by the APC, and (2) is not caused by
release of anti-inﬂammatory mediators into the extracel-
lular milieu [6, 18]. Similarly, monocytes and macrophages
exposed to apoptotic cells decrease secretion of IL-1b,
IL-12p70,IL-23andTNF-a,whilemaintainingorincreasing
the release of TGF-b1, IL-10, and prostaglandin E2 [1, 17,
19–21]. Soluble mediators released by phagocytes during
apoptotic cell clearance, not only prevent the inﬂammatory
response, but also contribute to the resolution of inﬂamma-
tion and tissue restoration. During bacterial pneumonia in
mice, alveolar macrophages that phagocytosed apoptotic
neutrophils secrete Hepatocyte Growth Factor, a mediator
that promotes proliferation of lung epithelial cells [22].
DC that acquire Ag from apoptotic cells present efﬁ-
ciently apoptotic cell-derived peptides to CD4 T cells and
cross-present the internalized Ag to MHC class-I-restricted
CD8 cytotoxic T cells [9, 23–25]. However, DC exposed to
apoptotic cells decrease their ability to stimulate T cells, a
phenomenon that seems to be related to the inhibitory
effect of apoptotic cells on the amount of expression of
MHC and co-stimulatory molecules, rather than to a defect
in the Ag-processing function of the APC [3–6].
How do apoptotic cells control the immunostimulatory
function of APC?
During the build up of the phagocytic synapse between the
apoptotic cell and the phagocyte, a series of Apoptotic-
Cell-Associated Molecular Patterns (ACAMP) present on
the surface of apoptotic cells bind to Pattern-Recognition
Receptors (PRR) expressed by the phagocytes. Membrane
receptors like MerTK, TIM-1, -3 and -4, the integrins avb3
and avb5, complement receptors (CR) 3 and 4, lectins,
scavenger receptors (i.e. CD14, CD36, CD68, SR-A and
LOX-1) and receptors for a2 macroglobulin (CD91), and
b2-glycoprotein I participate in apoptotic cell binding
and/or ingestion by immature DC or macrophages [26–29].
In addition, a number of soluble proteins, including the
complement fractions C1q and iC3b, milk fat globule
protein-E8 (also known as lactadherin), growth arrest-
speciﬁc gene-6 (GAS-6), protein S, collectins (i.e. man-
nose-binding lectin, surfactant proteins A and D), pent-
raxins, thrombospondin-1, and serum b2-glycoprotein I
function as opsonins, forming molecular bridges between
ligands on the membrane of apoptotic cells and PRR on the
surface of the phagocytes [26–29].
Apoptotic cells down-regulate inﬂammation and the
immunostimulatory function of APC via PRR-dependent
and—independent mechanisms. The relative contribution
of each PRR and the signaling pathways involved in the
immunoregulatory effects of apoptotic cells on APC are
beginning to be elucidated. Engagement of the thrombo-
spondin receptor CD36 inhibited maturation and function
of DC, that became unable to release IL-12 and secrete
high levels of IL-10 in response to DC-activation stimuli
[5]. Similarly, signaling via phosphatidylserine (PS)
receptors using liposomes containing PS prevented matu-
ration and reduced IL-12p70 secretion and T cell stimula-
tory function in human DC [30].
MerTK, a member of the Axl/Mer/Tyro3 receptor
tyrosine kinase expressed by DC and macrophages, is a
ligand for GAS-6, which binds to externalized PS on
apoptotic cells [31–34]. Signaling of DC via MerTK by
co-incubation with apoptotic cells activates the phospha-
tidylinositol 3-kinase (PI3K)/AKT pathway, which nega-
tively regulates NF-jB activation and the consequent DC
maturation [35]. Indeed, DC lacking MerTK expression or
treated with PI3K inhibitors became refractory to the
down-regulatory effect of apoptotic cells on LPS-induced
secretion of TNF-a and IL-12p70 [35].
The surface of apoptotic cell binds the complement
components C1q and iC3b. Macrophages and DC interact
with apoptotic cells via CR. Human monocyte-derived DC
generated in the presence of C1q display impaired matu-
ration, reduced secretion of IL-6, TNF-a and IL-12p70, and
decreased T cell allo-stimulatory function following non-
cognate (LPS) or cognate (CD40-signaling) stimulation
[36]. Interaction with iC3b-opsonized apoptotic cells pre-
vented up-regulation of MHC class-II Ag, CD86, CC
chemokine receptor (CCR)2, CCR5, and b2 integrins, but
increased expression of CCR7 in human DC [7]. Thus, DC
that uptake of iC3b-opsonized apoptotic cells in peripheral
tissues remain immature/semi-mature, but capable of
migrating in response to CCR7 ligands to secondary
Apoptosis (2010) 15:1083–1097 1085
123lymphoid organs and initiate or maintain T cell peripheral
tolerance. Incubation of mouse and human immature DC
with erythrocytes iC3b-opsonized or covered with Ab
against the iC3b-binding domain of CR3 (CD11b/CD18),
mimicked the down-regulatory effect of apoptotic cells on
secretion of pro-inﬂammatory cytokines, without affecting
release of TGF-b1[ 14, 37]. Human DC exposed to surro-
gate apoptotic cells capable of signaling exclusively
through CR3, processed and presented normally exogenous
Ag, but became impaired to prime efﬁciently naı ¨ve T cells
into effector cells [37]. By contrast, Behrens et al. [38]
have shown that the absence of iC3b in serum does not
alter the immunoregulatory effects of apoptotic cells on DC
in vitro, a phenomenon likely due to redundancy in the
apoptotic cell receptor system.
Apoptotic cells also modulate the function of DC
through more indirect mechanisms. Co-culture of DC with
apoptotic cells promoted secretion of interferon (IFN)-c
that up-regulated via autocrine and paracrine loops the DC
content of the active form of indoleamine 2,3-dioxygenase,
an enzyme that degrades the essential amino acid trypto-
phan into metabolites that inhibit T cell function [15]. DC
exposed to apoptotic cells released large amounts of nitric
oxide that impairs the T cell response [16].
Some of the inhibitory effects of apoptotic cells on
APC take place at the mRNA transcription level. In
macrophages, signals derived from the contact with
apoptotic cells, likely via interaction of externalized PS
with its receptors, reduced the level of tyrosine phos-
phorylation of the transcription repressor factor GC-BP,
enhancing its ability to bind the IL-12p35 promoter and
selectively repressing transcription of the IL-12p35 gene
[21].
Besides their potent immunoregulatory effects mediated
indirectly through phagocytes, apoptotic cells by them-
selves down-modulate inﬂammation and immunity. T cells
undergoing apoptosis released IL-10 and the latent and
active forms of TGF-b into the extracellular milieu [39,
40]. In T lymphocytes, programmed cell death promoted
synthesis of IL-10, whereas TGF-b secretion resulted from
release of existing cytokine pools stored in intracellular
membrane-bound compartments like mitochondria [39,
40]. In addition, apoptosis triggered de novo synthesis and
release of thrombospondin 1 in monocytes and neutrophils,
a protein that binds avidly to immature DC enhancing
engulﬁng of apoptotic cells and preventing DC maturation
in response to LPS stimulation [41]. Ariel et al. [42] have
shown that the chemokine receptor CCR5 is mobilized to
the cell surface of neutrophils and T cells undergoing
apoptosis. CCR5 expressed on the surface of apoptotic
leukocytes remained functional and sequestered efﬁciently
its ligands CCL3 and CCL5 from sites of inﬂammation,
constituting a mechanism of resolution of the inﬂammatory
response [42]. The mechanisms by which early apoptotic
cells down-regulate inﬂammation and the function of DC
are summarized in Fig. 1.
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Fig. 1 Anti-inﬂammatory and immunosuppressive mechanisms of
apoptotic cells. Leukocytes undergoing apoptosis release the immu-
nosuppressive cytokines IL-10 and TGF-b1, and soluble thrombo-
spondin 1 which functions as a bridge between apoptotic cells and
phagocytic APC and down-regulates the immunostimulatory function
of DC. Apoptotic leukocytes increase surface expression of CCR5
that sequesters the inﬂammatory chemokines CCL3 and CCL5,
facilitating the resolution of inﬂammation. Following interaction
or phagocytosis of apoptotic cells, DC (i) become resistant to
maturation/activation in response to pro-inﬂammatory stimuli; (ii)
increase IL-10 and TGF-b1 secretion, release nitric oxide, and
augment their intracellular content of functional indoleamine
2,3-dioxygenase (IDO); and (iii) up-regulate CCR7 expression, which
allows peripheral tissue-resident DC that engulfed apoptotic cells to
migrate to secondary lymphoid organs. Some of the immunosuppres-
sive effects of apoptotic cells on APC occur at the level of mRNA
transcription or processing
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tolerance
Self-reactive T cells that escape central (thymic) deletion
migrate to secondary lymphoid organs. Therefore, an efﬁ-
cient mechanism of peripheral tolerance must monitor and
de-activate, delete or regulate auto-reactive T cell clones in
periphery to prevent autoimmunity [43, 44]. Elegant
experiments in mice expressing transgenic Ag controlled
by tissue-speciﬁc promoters have shown that, in normal
conditions, constitutive migration of APC from peripheral
tissues to draining lymphoid organs, results in presentation
of tissue-derived Ag to T cells [45, 46]. However, migra-
tion of peripheral APC carrying the transgenic self-Ag
acquired from neighboring parenchymal cells resulted in
suppression of Ag-speciﬁc CD4 and CD8 T cells [45, 46].
These ﬁndings, together with results obtained from exper-
iments of in situ-targeting of DC in vivo [47, 48], led to the
hypothesis that during induction/maintenance of peripheral
T cell tolerance, semi-mature DC mobilized from periph-
eral tissues or resident in secondary lymphoid organs,
present self-Ag in a pro-tolerogenic fashion to down-reg-
ulate those auto-reactive T cell clones that escaped thymic
deletion [43].
Every day, billions of tissue cells die by apoptosis as
part of the physiologic mechanism of cell turn-over. These
apoptotic cells constitute an excellent source of self-Ag for
immature DC in periphery. DC with engulfed apoptotic
bodies or cellular fragments derived from neighboring
parenchymal cells have been reported within or in the
vicinity of epidermis, and intestine, gastric or vaginal
epithelia [49–52]. Importantly, although interaction or
engulfment of apoptotic cells prevents DC activation/
maturation, it does not affect the ability of immature/semi-
mature DC to migrate to secondary lymphoid organs. DC
that engulf apoptotic cells, although remain immature,
increase their surface expression of CCR7, a chemokine
receptor required for peripheral DC to migrate to secondary
lymphoid organs in response to the chemokines CCL19 and
CCL21 [7, 53]. Indeed, DC with internalized apoptotic cell
fragments derived from intestinal epithelial cells and gas-
tric parietal cells have been detected in Peyer’s patches and
mesenteric lymph nodes, and in stomach-draining lymph
nodes, respectively [50, 51].
The presence of DC with internalized apoptotic cells in
secondary lymphoid organs is not always due to migration
of peripheral DC. In mice, spleen-resident CD11c
hi CD8
-
or CD8a
? DC, unlike CD11c
int plasmacytoid DC, capture
efﬁciently blood-borne apoptotic leukocytes [18]. Simi-
larly, in humans, it has been shown that myeloid DC,
unlike plasmacytoid DC, internalize apoptotic cells [54].
Experiments of adoptive transference of TCR transgenic
T cells in mice have shown that both types of conventional
CD11c
hi DC (tissue-migratory and secondary lymphoid
organ-resident) are capable of presenting apoptotic cell-
derived peptides to T cells [51]. In vivo, under steady-state
conditions, presentation by splenic DC of apoptotic cell-
derived peptides loaded in MHC class-I or -II molecule
leads to clonal deletion of Ag-speciﬁc CD8 or CD4 T cells,
respectively, and generation of Ag-speciﬁc regulatory T
cells (Treg) [55–58]. Recent evidence indicates that
apoptotic cells may exert immunosuppressive effects via
generation of CD19
? regulatory B cells, which inﬂuence
the function of effector T cells [59].
Together, the accumulated evidence indicates that inter-
nalization of endogenous apoptotic cells by immature/semi-
mature APC, through an extremely efﬁcient mechanism of
apoptotic cell clearance, is followed by deletion and/or
regulation of self-reactive lymphocytes and therefore, pre-
vention of autoimmunity. Indeed, mice with deﬁciencies in
molecules critical for recognition, internalization, or lyso-
somal DNA degradation of apoptotic cells, including C1q,
C4, IgM, the pentraxin Serum Amyloid P, MerTK, milk fat
globule protein-E8, class A scavenger receptors, or lyso-
somal DNase II develop systemic autoimmune disorders
[60–68]. In humans, systemic lupus erythematosus is asso-
ciated with genetic deﬁciencies in complement factors
[69, 70], and with defective phagocytosis of apoptotic cells
[71, 72].
Apoptotic cells as therapeutic tools in transplantation
The concept that processing of endogenous apoptotic cells
byquiescentAPCinsecondarylymphoidorgansisnecessary
for induction and/or maintenance of peripheral self-toler-
ance in the steady-state [73], led to the idea that systemic
(i.v.) administration of donor leukocytes undergoing apop-
tosis could be used to deliver in situ the entire repertoire of
donor allo-Ag together with immunoregulatory signals to
recipient’s APC, to induce donor-speciﬁc immunosuppres-
sion in transplantation [reviewed in 74–76]. Since internal-
ization of apoptotic cells prevents APC maturation/
activation, presentation of apoptotic cell-derived allo-pep-
tides by recipient’s quiescent APC expressing a low ratio of
T cell co-stimulatory versus co-regulatory molecules, could
be employed therapeutically to promote deletion, anergy
and/or regulation of donor-reactive T cells and therefore, to
prolong allograft survival.
Apoptotic cell therapies restrain allo-immunity
and acute rejection in cardiac transplantation
Therapies based on administration of donor-derived apop-
totic leukocytes have been proven to exert beneﬁcial
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administration of a single dose of donor splenocytes in
early apoptosis, 7 days before transplantation, prolonged
signiﬁcantly survival of heterotopic (abdomen) vascular-
ized cardiac allografts in mice and rats [57, 77]. The ben-
eﬁcial effect of apoptotic cells was donor-speciﬁc, took
place in different donor and recipient strain combinations,
and depended on the biological properties of the apoptotic
cells, since i.v. injection of donor splenocytes undergoing
primary necrosis (induced by freezing-thawing) did not
affect graft survival [57, 77]. Prolongation of cardiac
allograft survival was independent on the method
employed to induce apoptosis, as similar results were
obtained with apoptotic cells generated by UV-B- or
c-irradiation [77]. However, the therapeutic effect depen-
ded critically on the timing of administration of apoptotic
cells, with optimal results achieved when donor apoptotic
splenocytes were injected 7 days prior to transplantation
[77].
Trafﬁcking studies have demonstrated that allogeneic
apoptotic splenocytes injected i.v. are internalized within a
few hours by red pulp macrophages and by specialized
phagocytes and DC of the marginal zone of the spleen [14,
18, 57, 78]. In mice, splenic CD11c
hi DC (mainly the
CD8a
? DC of the marginal zone), unlike the CD11c
int
plasmacytoid DC, internalized in vivo early apoptotic cells
administered i.v. [18, 79]. At later time points, these
marginal zone DC containing phagocytosed apoptotic cell
fragments migrated to the T cell areas of the splenic fol-
licles for cross-presentation of the apoptotic cell-derived
Ag [14, 79].
Since phagocytosis of apoptotic cells prevents APC
maturation in vivo, DC that internalize and process donor
apoptotic cells present apoptotic cell-derived allopeptides
to donor-reactive T cells in the context of low co-stimu-
lation [57]. This sequence of events leads to deﬁcient
activation, followed by transient proliferation and deletion
of donor-reactive T cells, as demonstrated in vivo by
injecting systemically allogeneic apoptotic splenocytes into
host mice previously reconstituted with allo-reactive TCR
transgenic CD4 T cells [57]. In this model, presentation of
donor apoptotic cell-derived allopeptides by immature/
semi-mature DC in the spleen promoted transient prolif-
eration of anti-donor CD4 T cells unequipped for homeo-
static survival. These unﬁtted CD4 T cells expressed lower
levels of the anti-apoptotic protein Bcl-XL and the cytokine
receptors IL-7Ra (CD127), IL-15Ra and the common
cytokine receptor gamma chain (cc or CD132), than control
T cells fully activated [57]. I.v. injection of BALB/c
apoptotic splenocytes into C57BL/6 J hosts adoptively
transferred with 1H3.1 TCR transgenic CD4 T cells (spe-
ciﬁc for the BALB/c IEa52–68 peptide presented by C57BL/
6J IA
b MHC class-II molecules) was associated 14 days
later, with (1) increased percentage of splenic 1H3.1 T cells
expressing the Treg marker FoxP3 and (2) increased IL-10
and reduced IFN-c secretion of splenocytes in response to
ex vivo re-stimulation with the BALB/c (donor) IEa52–68
peptide [18]. Similarly, donor apoptotic cell therapy
decreased drastically cross-priming of donor-reactive 2C
TCR transgenic CD8 T cells in vivo in the same mouse
model [18]. These results explain why, 7 days post-trans-
plant, recipient mice and rats pre-treated with donor
apoptotic cells reduced drastically the systemic anti-donor
type 1 T cell response, and exhibited minimal parenchymal
damage and decreased leukocyte inﬁltration in the allo-
grafts, compared to untreated controls [57, 77].
It is likely that, for clinical application in transplanta-
tion, apoptotic cell therapies will be administered in
combination with reduced levels of pharmacological
immunosuppression, to enhance the beneﬁcial effects of
apoptotic cells and minimize the side-effects caused by the
immunosuppressive regimen. In this regard, infusion of
donor apoptotic splenocytes, plus a single suboptimal dose
of anti-CD40 ligand blocking Ab (to prevent the stimulatoy
effect of CD40-signaling on recipient’s APC) prolonged
indeﬁnitely ([100 days) survival of cardiac allografts in
mice [57]. Interestingly, the long-term allografts showed
minimal tissue damage and were inﬁltrated by small foci of
leukocytes composed mainly of CD4
? FoxP3
? T cells with
intracellular content of IL-10 and TGF-b1[ 57]. The fact
that transference of splenic T cells from long-term C57BL/
10J recipients pre-treated with donor apoptotic splenocytes,
into naı ¨ve (untreated) C57BL/10J mice prolonged signiﬁ-
cantly survival of cardiac allografts from the same donor,
but not third-party grafts, indicates that in that model donor
apoptotic cell therapy promoted generation/expansion of
donor-speciﬁc Treg [57].
Donor apoptotic splenocytes have also been used indi-
rectly in combination with tolerogenic DC therapies. Intra-
portal administration, 7 days prior to transplantation, of
recipient’s bone marrow-derived maturation-resistant DC
loaded in vitro with donor apoptotic splenocytes prolonged
signiﬁcantly survival of heart allografts in otherwise non-
immunosuppressed mice [80].
Recipient’s APC mediate immunoregulatory effects
of apoptotic cell therapies in cardiac transplantation
There is evidence that the effect of apoptotic cell therapy
on cardiac allograft survival is mediated, at least in part,
through recipient’s APC. Adoptive transference of freshly-
isolated splenic CD11c
? DC of C57BL/10J mice, pre-
treated (i.v., 24–36 h earlier) with BALB/c apoptotic
splenocytes, into naı ¨ve C57BL/10J, prolonged signiﬁcantly
survival of BALB/c hearts transplanted 7 days later [57].
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?
DC in the transferred inoculum [57], and agrees with
similar ﬁndings reported in a mouse model of adoptive
transfer of inhibition of contact hypersensitivity induced by
i.v. injected haptenated apoptotic cells [56].
In a cardiac transplantation model in mice, transient
depletion of CD11c
hi DC without affecting the subset of
CD11c
int plasmacytoid DC, at the time of i.v. administra-
tion of allogeneic apoptotic splenocytes was followed by
lack of proliferation of allo-reactive TCR transgenic CD4 T
cells in the spleen [18]. Together, these results suggest that
the beneﬁcial effect of donor apoptotic cell therapies on
cardiac allograft survival are mediated by recipient’s
CD11c
hi DC (likely the CD8a
? DC subset in mice) resi-
dent in secondary lymphoid organs. In this model, splenic
CD11c
hi DC that capture donor apoptotic splenocytes from
circulation remained quiescent in vivo and resistant to
maturation in response to DC-activating stimuli [18].
However, their ability to present allo-peptides from blood-
borne apoptotic cells is short-lived, reaching a plateau
3 days after apoptotic cell i.v. administration [18]. Pre-
sentation of donor apoptotic cell peptides by recipient’s
quiescent DC was critical for prolongation of cardiac
allograft survival, since the effect was abrogated by
induction of DC maturation in situ through CD40-signaling
[57].
Sun et al. [77] have shown that blockade of phagocytosis
with gadolinium chloride, before i.v. injection of apoptotic
splenocytes, abrogates their therapeutic effect on cardiac
allograft survival in rats. This ﬁnding indicates that imma-
ture DC and/or macrophages via (1) phagocytosis, process-
ing and presentation of apoptotic cell-derived allo-Ag,
and/or (2) secretion of anti-inﬂammatory/immuno-suppres-
sive mediators, are critical for the immunoregulatory effects
of exogenous apoptotic cells in cardiac transplantation.
Indeed, the same group [77] demonstrated indirectly that
donor apoptotic splenocytes infused i.v. exert their immu-
noregulatory effects by interacting with PRR expressed by
recipient’s APC. In this study, blockade of externalized PS
byincubationwithsolubleannexin-Vreduceddrasticallythe
ability of donor apoptotic splenocytes to prolong heart
allograft survival in rats, compared to controls injected with
untreated apoptotic cells [77].
In other transplantation models, recipient’s macro-
phages, instead of DC, seem to mediate the therapeutic
effect of apoptotic cells. Transient deletion of CD11c
hi DC
in transgenic mice encoding for the diphtheria toxin
receptor driven by the CD11c promoter, did not affect the
graft-facilitating effect of apoptotic cells on bone marrow
transplantation [78]. By contrast, depletion of host’s mac-
rophages by infusion of clodronate-loaded liposomes
reduced signiﬁcantly apoptotic cell-induced donor bone
marrow engraftment [78]. In a mouse model of induced
experimental autoimmune encephalomyelitis, in which i.v.
administration of apoptotic cells containing the self-Ag
myelin olygodendrocyte glycoprotein prevented autoim-
munity, splenic marginal zone macrophages were critical
for the beneﬁcial effect of the injected apoptotic cells [81].
These macrophages controlled the clearance of the exog-
enous apoptotic cells and their selective engulfment by
splenic CD8a
? DC, which were likely the ﬁnal responsible
cells for the tolerogenic effect [81].
Apoptotic cell therapies in chronic rejection
Chronic rejection of solid allografts, in particular kidney,
heart and lung, is a major problem that prevents long-term
graft survival in an elevated percentage of recipients.
Importantly, currently employed immunosuppressive regi-
mens fail to prevent chronic rejection. One of the key
pathological features of chronic rejection is the presence, in
medium and small size arteries of the graft, of chronic
allograft vasculopathy (CAV). Vessels affected by CAV
develop endothelialitis, intimal thickening, elastic ﬁber
disruption, adventitial ﬁbrosis and leukocyte inﬁltration,
which together lead to progressive reduction of the vas-
cular lumen and its obstruction by thrombosis. CAV is
caused by non-immune and by innate and adaptive immune
mechanisms, the latter ones through donor-reactive T cells
and alloAb.
The adaptive immune response that in part causes
chronic rejection is elicited via the indirect pathway of
allorecognition, a mechanism by which donor-reactive T
cells recognize donor allo-peptides presented by self
(recipient’s)-MHC molecules. Indirect pathway T cells are
also critical to provide help to donor-reactive B cells,
which then differentiate into the plasma cells that secrete
alloAb. Since i.v. injected donor apoptotic cells are pro-
cessed by recipient’s APC for presentation to indirect
pathway T cells, apoptotic cell therapies can be used as a
therapeutic approach to (1) down-regulate the indirect
pathway T cell response; (2) reduce the level of cognate
interaction and cooperation between indirect pathway T
cells and allo-reactive B cells, which is critical for gener-
ation of alloAb; and (3) prevent, delay or ameliorate signs
of chronic rejection.
In mice, administration of donor apoptotic splenocytes
7 days prior to transplant, minimized substantially the
histopathological features of CAV in fully-mismatched
aortic allografts, an established experimental model of
CAV [18]. The effect was donor- and apoptotic cell-spe-
ciﬁc, since third-party apoptotic cells, or donor splenocytes
alive or undergoing primary necrosis (induced by freezing-
thawing) did not prevent development of CAV in the same
model. Sixty days after transplant, those recipients that
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decrease in: (1) the number of indirect pathway (poly-
clonal) T cells secreting IFN-c and (2) the amount of cir-
culating alloAb, compared to controls [18].
Nouri-Shirazi and Guinet [82] have shown in vitro that
human immature DC incubated with allogeneic apoptotic
cells promote allo-speciﬁc CD4 T cell anergy via the
indirect pathway. This ﬁnding suggests that systemic
administration of donor apoptotic cells or alternatively,
immature DC loaded with donor apoptotic cells, could
restrain the indirect T cell response during the chronic
phase of organ transplantation in humans.
Apoptotic cell therapies in bone marrow
transplantation
The therapeutic potential of allogeneic bone-marrow or
hematopoietic stem cell transplantation for treatment of
malignant and genetic hematologic disorders has been
limited by immunologic complications. The presence of
remaining functional donor-reactive T cells and NK cells,
resistant to the conditioning regimen in the recipient,
triggers allograft rejection and prevents engraftment of
donor bone marrow cells. On the donor’s side, T cells that
recognize recipient’s MHC Ag and adoptively transferred
with the bone marrow allograft are the cause of graft-ver-
sus-host-disease (GvHD). Apoptotic cell therapies have
been used to facilitate bone marrow cell engraftment and
prevent GvHD.
In a restrictive model of bone marrow transplantation in
mice, co-administration of apoptotic cells (i.v.) the day of
the transplant enhanced bone marrow engraftment and
prevented GvHD in different donor-recipient strain com-
binations [83]. Prevention of GvHD was associated to the
in vivo expansion of donor-derived CD4
? CD25
? Treg,
which somehow restrained the anti-recipient response to
peripheral tissues that leads to GvHD [78]. The therapeutic
effect of apoptotic cells was independent of the stimulus
employed to trigger cell death, and interestingly, was
unspeciﬁc since it occurred following administration of
third-party or xenogeneic (human) apoptotic leukocytes
[83]. However, this apparent lack of allo-speciﬁcity could
be due to the fact that the bone marrow allograft and the
bolus of apoptotic cells were administered simultaneously,
providing recipient’s APC with donor Ag and at the same
time with bystander immunoregulatory signals supplied by
the injected apoptotic cells regardless their origin. Impor-
tantly, in this model, addition of apoptotic cells to the bone
marrow allografts also reduced Ab-mediated anti-donor
responses [84], and increased the percentage of donor-
derived CD4 T cells with phenotype (CD25
? FoxP3
?
CD62L
hi CTLA-4
hi) and function of Treg [78]. The ability
of apoptotic cell therapy to promote bone marrow
engraftment, down-regulate alloAb secretion, and augment
the percentage of Treg was mediated through TGF-b
released likely by phagocytes during their interaction with
the injected apoptotic cells and/or directly by the apoptotic
cells [78].
Role of apoptotic cells in extracorporeal photopheresis
in transplantation
Extracorporeal photopheresis (ECP) is a technique in which
a fraction of the patient’s peripheral blood is transiently
removed and separated by leukapheresis into leukocyte-
depleted blood and leukocyte-enriched plasma. The former
is returned into the patient without further treatment,
whereas the mononuclear cell-enriched fraction is incu-
bated ex vivo with the photosensitizing drug 8-methoxyp-
soralen and exposed to UV-A radiation (350 nm), and then
reinfused in a close-loop, patient-connected system. In the
presence of UV-A light, 8-methoxypsoralen covalently
binds to DNA pyrimidine bases, cell-surface and cytoplas-
mic molecules, priming the target leukocytes for apoptosis.
The ability of ECP to down-regulate the T cell response
in vivo has been demonstrated in auto-, allo- and xeno-
immunity [85–87]. In humans, addition of ECP to con-
ventional pharmacologic immunosuppression decreased the
risk of acute rejection in recipients of cardiac allografts [88]
and was effective for treatment of ongoing episodes of acute
heart rejection during the ﬁrst year after transplantation [89,
90]. ECP has been also tested with success in patients with
kidney, lung, liver or face allograft rejection [91–95], or
GvHD [96, 97], in particular in cases refractory to con-
ventional pharmacologic immunosuppression.
Despite the promising results in the clinics, the mecha-
nism(s) by which ECP down-regulates the immune
response in vivo remains unclear. The beneﬁcial effect of
ECP in transplantation can not be attributed simply to the
induction of apoptosis in donor-reactive lymphocytes,
since less than 10% of the peripheral leukocytes are
exposed ex vivo to 8-methoxypsoralen and UV-A radia-
tion. Interestingly, patients treated for long-term with ECP
do not exhibit higher incidence of infections or malignan-
cies [98] and respond normally to novel and recall Ag [99],
suggesting that treatment with ECP does not cause gen-
eralized immunosuppression. These observations have led
to the conclusion that the therapeutic effects of ECP are
mediated via systemic Ag-speciﬁc immunoregulation.
Among the cells irradiated during ECP, circulating
lymphocytes, monocytes and DC are sensitive to apoptosis
[100–105], generating apoptotic bodies and blebs with
immunoregulatory properties [106]. Even before dying,
human DC treated with 8-methoxypsoralen and UVA,
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their ability to drive Th1 polarization [107, 108]. Once
reinfused, the ECP-treated leukocytes are retained pri-
marily in the spleen and liver [100, 101], likely by inter-
nalization by tissue-resident macrophages and immature
DC, as shown for UV-B-irradiated splenocytes injected i.v.
[14]. In humans, immature DC internalized efﬁciently
ECP-treated leukocytes [104], and incubation with ECP-
treated leukocytes increased IL-10 secretion and prevented
up-regulation of co-stimulatory molecules in DC, and
augmented the IL-10 and IL-1R antagonist mRNA content
in peripheral leukocytes, even in presence of LPS [102,
109]. In one study, ECP-treated leukocytes increased their
release of HLA-G molecules which play an important role
in down-regulation of T cell immunity [103]. Together,
these ﬁndings suggest that the reinfused ECP-treated leu-
kocytes enhance the pro-tolerogenic function of those
quiescent DC (and likely macrophages) that interact with
them. In this regard, transference of ECP-treated spleno-
cytes from mice sensitized with dinitroﬂuorobenzene into
naı ¨ve mice caused inhibition of contact hypersensitivity in
a hapten-speciﬁc way, and the inhibition was lost when the
transferred splenocytes were depleted of CD4
? or CD25
?
lymphocytes [100, 101]. This latter ﬁnding suggests that
ECP exerts immunoregulatory effects, at least partly, via
Ag-speciﬁc Treg.
There is evidence that the regulatory effect of ECP on
allo-immunity is also mediated, to some extent, through of
allo-speciﬁc Treg. Transference of splenic CD4
? CD25
? T
cells from ECP-treated mice transplanted with fully-mis-
matched hearts, prolonged survival of cardiac allografts
from the same donor strain in naı ¨ve recipients [110].
In vivo depletion of Treg prevented the beneﬁcial effect of
ECP in a mouse model of GvHD [111]. In humans,
recipients of heart, lung, or kidney allografts or with GvHD
treated with ECP in addition to conventional immunosup-
pression, exhibited a higher frequency of peripheral T cells
with Treg phenotype (CD4
? CD25
? FoxP3
? CD69
-) and
function [104, 112–114]. Treatment with ECP also aug-
ments the regulatory function of peripheral CD4
? CD25
?
FoxP3
? Treg by increasing their CD39-mediated produc-
tion of adenosine, a soluble immunosuppressive mediator
of T cell activation [115]. Further studies will reveal the
speciﬁcity of the CD4
? Treg generated following ECP.
Role of apoptotic cells in living cell-therapies and
Ab-based immunosuppression in transplantation
In recent years, there has been increasing evidence that the
beneﬁcial effects achieved with living cell-based therapies
(i.e. blood transfusion, tolerogenic DC administered sys-
temically), or anti-CD3 Ab-induced immunosuppression
are mediated through generation of apoptotic cells in vivo
(Fig. 2).
One of the ﬁrst cell-based therapies employed to restrain
the anti-donor response and prolong solid allograft survival
consisted in administration of randomly selected, haplo-
type-shared or donor-speciﬁc transfusions (DST), in most
cases in combination with pharmacological immunosup-
pression [116–121]. It was initially assumed that the
immunosuppressive effect of DST was mediated through
direct interaction of the transfused leukocytes expressing
donor MHC Ag with anti-donor T cells in secondary
lymphoid organs [reviewed in 122]. However, different
laboratories [123–125] have independently shown that the
DST effect requires presentation of donor allopeptides in
the context of recipient’s MHC molecules to anti-donor
T cells via the indirect pathway. Importantly, once injected
i.v., non-self leukocytes have a limited life-span since they
become targets of recipient’s NK cells. These ﬁnding
suggest that, as soon as the transfused leukocytes become
apoptotic in vivo, they are internalized by recipient’s qui-
escent APC, which then present the apoptotic cell-derived
donor allopeptides to indirect pathway T cells. Since the
transfused leukocytes are likely engulfed by phagocytic
APC as soon as they show early signs of apoptosis, it is
expected that internalization of apoptotic cells will deliver
a potent immunoregulatory signal plus donor Ag to reci-
pient’s APC, leading to down-modulation of the anti-donor
response.
The use of DST as clinical therapy was discontinued in
the early 80s due to the risk of sensitization and the advent
of new immunosuppressive agents. More recently, tolero-
genic DC-based therapies based on i.v. administration of
in vitro-generated donor or recipient-derived DC have been
used with relative success to delay or prevent solid allo-
graft rejection or GvHD in murine models [reviewed in
126]. In tolerogenic DC-based therapies, immature, matu-
ration-resistant, or alternatively-activated DC are generated
in vitro by different culture, pharmacologic or genetic
methods and then administered i.v. into graft recipients,
with optimal results in murine models when the DC are
administered 7 days prior to transplantation.
As originally assumed for the DST effect, the general
idea is that the injected DC interact directly with anti-donor
T cells in vivo, leading to anergy, deletion and/or regula-
tion. To our knowledge this concept has never been tested
in vivo, since all studies have examined the capacity of the
therapeutic DC to down-modulate the anti-donor T cell
response in vitro, or in ex vivo assays after transplantation.
Another possibility is that, as demonstrated in DST, reci-
pient’s APC present donor alloAg acquired from the ther-
apeutic DC injected i.v.. In agreement with that idea, in
certain mouse strain combinations, repetitive i.v. injection
of UV-B irradiated allogeneic immature DC prevented
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intranasal administration of apoptotic DC in mice sup-
pressed LPS-induced lung inﬂammation, inhibited host’s
DC maturation, and inducted Ag-speciﬁc CD4 Treg [128],
and i.v. infusion of chemically-ﬁxed immature DC pro-
longed signiﬁcantly survival of cardiac allografts in mice
[129]. Together, these ﬁndings strongly suggest that the
exogenous DC do not have to be alive to down-regulate the
anti-donor response in vivo. Interestingly, in mouse allo-
speciﬁc TCR transgenic models, donor-derived tolerogenic
DC injected i.v. in prospective graft recipients did not
interact directly with donor-reactive CD4 or CD8 T cells
in vivo [130]. Instead, the injected DC were short-lived,
internalized as apoptotic cells by recipient’s quiescent
CD11c
hi DC in the spleen, which presented the donor
allopeptides in the context of recipient’s MHC molecules
to indirect pathway T cells. This phenomenon led to donor-
speciﬁc T cell deletion and increased percentage of donor-
reactive T cells expressing the Treg marker FoxP3. These
ﬁndings strongly suggest that systemic administration of
tolerogenic DC and DST could function indirectly as
apoptotic cell-based therapies, by delivering donor Ag in
combination with potent regulatory signals to those reci-
pient’s APC that phagocyte the injected cells as soon as
they become apoptotic in vivo.
Administration of CD3-speciﬁc monoclonal Ab results
in rapid depletion of T cells, generation of CD4 Treg, and
induction of long-term immune tolerance. Although ther-
apy with anti-CD3 monoclonal Ab has been employed to
treat autoimmune disorders and transplant rejection, its
mechanism of action in vivo has been unveiled recently. In
a mouse model of experimental autoimmune encephalo-
myelitis, Perruche et al. [131] have shown that apoptotic T
cells induced by the CD3 Ab are internalized by macro-
phages and immature DC in secondary lymphoid organs. In
response to the apoptotic cell interaction, these APC up-
regulated secretion of TGF-b, which induced CD4 FoxP3
Treg that together with the T cell depletion promoted
immune tolerance. In fact, in vivo depletion of macro-
phages and immature DC by administration of clodronate
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Fig. 2 Summary of the role of apoptotic cells in different immuno-
suppressive therapies. Apoptotic cell therapy, ECP, DST, tolerogenic
DC therapies and anti-CD3 Ab immunotherapy likely modulate
Ag-speciﬁc immune responses and inﬂammation in transplantation by
a common mechanism: in vivo generation of apoptotic cells.
Therapeutically-administered (i.v.) or -induced apoptotic cells deliver
potent immunosuppressive signals plus the entire repertoire of donor
Ag (the latter in apoptotic cell therapy, DST and tolerogenic DC
therapies) to quiescent APC of secondary lymphoid organs. Presen-
tation of donor Ag by these quiescent APC induces defective
activation of indirect pathway CD4 T cells followed by T cell deletion
and generation of Treg. As a consequence of the regulatory effects of
apoptotic cells on donor-reactive T lymphocytes, allo-speciﬁc B cells
do not receive adequate help from indirect pathway CD4 T cells and
therefore, are unable to differentiate into the plasma cells that secrete
alloAb
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prevention and treatment of the autoimmune disease,
linking the effect of CD3 Ab to the potent immunoregu-
latory effect of the therapeutically generated apoptotic cells
on phagocytic APC [131].
Concluding remarks
Since the initial observation that apoptotic cells exert
potent regulatory effects on phagocytes of the immune
system, in particular APC, numerous laboratories have
employed apoptotic cell-based therapies to promote donor-
speciﬁc immunosuppression in transplantation. Most of the
work has being focused in: (1) unveiling the molecular
mechanisms behind the immunosuppressive effect; (2)
developing practical methods for generation of pro-toler-
ogenic and clinical-grade apoptotic cells; (3) augmenting
their regulatory capacity, by modifying the apoptotic cells
or by using them in combination with suboptimal phar-
macologic immunosuppression; and (4) ﬁnding the optimal
route for their delivery.
We have learnt that the use of non-stressed leukocytes
undergoing apoptosis, administered i.v., in doses that do
not saturate the physiologic mechanisms of apoptotic cell
clearance are critical factors to be considered to down-
regulate inﬂammatory and immune responses with apop-
totic cells. We have also started to connect the dots and
realize that other (living) cell-based therapies previously
used, currently employed, or under development in trans-
plantation may function simply through generation of
apoptotic cells in the graft recipients. However, as in any
other scientiﬁc ﬁeld, novel ﬁndings lead to new questions.
In this regard, it would be interesting to know: what is the
probability of triggering autoimmunity or causing allo-
sensitization in transplant recipients following single or
repetitive administration of apoptotic cells? How could
apoptotic cells be preserved or their immunosuppressive
effects enhanced for therapeutic applications? Could the
immunoregulatory effect of apoptotic cells be mimicked by
administering artiﬁcial liposomes bearing ACAMP on their
surface? Since previous studies have been conducted in
unprimed animals, what is the immunosuppressive poten-
tial of apoptotic cell therapies in recipients with high
numbers of allo-reactive memory T cells? What is the
therapeutic potential of apoptotic cell therapies in non-
human primate models of transplantation, a transitional
model that should be tested before embarking in clinical
trials? Some of the questions are currently being investi-
gated. Only time and more experiments will tell us whether
the peculiar biological properties of apoptotic cells could
be employed more efﬁciently for treatment of transplant
rejection or autoimmune disorders.
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